MetLife, Inc. $MET Shares Sold by KMG Fiduciary Partners LLC

KMG Fiduciary Partners LLC reduced its position in MetLife, Inc. (NYSE:MET) by 91.7% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 5,192 shares of the financial services provider’s stock after selling 57,138 shares during the period. KMG Fiduciary Partners LLC’s holdings in MetLife were worth $439,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. grew its position in shares of MetLife by 12.1% in the fourth quarter. Vanguard Group Inc. now owns 72,555,335 shares of the financial services provider’s stock valued at $5,727,518,000 after purchasing an additional 7,805,814 shares during the period. Pzena Investment Management LLC increased its stake in MetLife by 22.9% in the fourth quarter. Pzena Investment Management LLC now owns 11,883,338 shares of the financial services provider’s stock valued at $938,071,000 after purchasing an additional 2,211,315 shares during the last quarter. Norges Bank purchased a new position in MetLife during the fourth quarter worth about $639,986,000. Invesco Ltd. boosted its stake in MetLife by 2.6% in the 4th quarter. Invesco Ltd. now owns 7,012,198 shares of the financial services provider’s stock worth $553,543,000 after buying an additional 176,811 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in MetLife by 2.5% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,201,175 shares of the financial services provider’s stock worth $410,581,000 after buying an additional 126,098 shares during the last quarter. 94.99% of the stock is currently owned by institutional investors and hedge funds.

MetLife News Roundup

Here are the key news stories impacting MetLife this week:

• Positive Sentiment: JPMorgan raised its price target for MetLife from $106 to $108 and maintained an “overweight” rating. The new target implies approximately 11.6% upside from the referenced $96.78 level, signaling continued confidence in the insurer’s earnings and valuation. Benzinga report
• Positive Sentiment: Keefe, Bruyette & Woods also increased its price target from $105 to $108 and reaffirmed an “outperform” rating. The second target increase reinforces the constructive analyst view of MetLife’s prospects. Benzinga report Ticker Report article
• Neutral Sentiment: MetLife Pet Insurance announced a partnership with America’s VetDogs to help co-raise a future service dog for a veteran or first responder with disabilities. The initiative may enhance brand reputation and community engagement, but is unlikely to materially affect near-term financial results. MetLife Pet Insurance and America’s VetDogs partnership
• Neutral Sentiment: MetLife highlighted benefits and employee well-being in its 2025 Sustainability Report. The disclosure may support long-term stakeholder and corporate-responsibility goals, though it is not an immediate earnings catalyst. MetLife 2025 Sustainability Report

MetLife Stock Performance

MetLife stock opened at $96.78 on Wednesday. The stock’s 50-day moving average is $90.68 and its 200-day moving average is $81.14. The company has a market cap of $62.27 billion, a price-to-earnings ratio of 18.54, a price-to-earnings-growth ratio of 0.75 and a beta of 0.78. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.20 and a quick ratio of 0.20. MetLife, Inc. has a 12 month low of $67.33 and a 12 month high of $100.93.

MetLife (NYSE:MET) last issued its earnings results on Wednesday, August 5th. The financial services provider reported $2.43 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.30 by $0.13. The business had revenue of $13.52 billion during the quarter, compared to analysts’ expectations of $19.67 billion. MetLife had a return on equity of 23.39% and a net margin of 4.57%.The company’s revenue for the quarter was up 10.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.02 EPS. Equities analysts anticipate that MetLife, Inc. will post 9.75 earnings per share for the current year.

MetLife declared that its Board of Directors has approved a share buyback plan on Wednesday, August 5th that allows the company to repurchase $3.00 billion in outstanding shares. This repurchase authorization allows the financial services provider to reacquire up to 4.8% of its shares through open market purchases. Shares repurchase plans are often an indication that the company’s management believes its stock is undervalued.

MetLife Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 4th will be given a dividend of $0.5925 per share. This represents a $2.37 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date of this dividend is Tuesday, August 4th. MetLife’s payout ratio is 45.40%.

Analyst Upgrades and Downgrades

MET has been the subject of a number of research analyst reports. UBS Group upped their price objective on shares of MetLife from $102.00 to $105.00 and gave the company a “buy” rating in a research note on Wednesday, July 8th. Morgan Stanley raised their target price on shares of MetLife from $93.00 to $103.00 and gave the stock an “overweight” rating in a research report on Monday, July 6th. Bank of America lowered their target price on shares of MetLife from $103.00 to $99.00 and set a “buy” rating for the company in a report on Tuesday, April 14th. Piper Sandler increased their price target on shares of MetLife from $86.00 to $90.00 and gave the stock a “neutral” rating in a research note on Wednesday, June 24th. Finally, Keefe, Bruyette & Woods lifted their price target on shares of MetLife from $105.00 to $108.00 and gave the company an “outperform” rating in a report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $101.07.

MetLife Profile

MetLife, Inc is a global provider of insurance, annuities and employee benefit programs. Headquartered in New York City, the company offers a range of risk protection and retirement solutions to individuals, employers and institutional clients. Its core businesses include life insurance, group benefits, retirement products such as annuities, and supplemental health products including dental and disability coverage.

In addition to traditional life and group insurance, MetLife provides workplace benefits and voluntary products distributed through employer-sponsored programs.